Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HRH2 | P25021 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5544791 | 0.90 | LTA4H (0.80) | LTA4HTMEM97SIGMAR1HTR1AHTR7 | |
| SCHEMBL6398998 | 0.90 | LTA4H (0.80) | LTA4HTMEM97SIGMAR1HTR1AHTR7 | |
| SCHEMBL6278104 | 0.90 | LTA4H (0.80) | LTA4HTMEM97SIGMAR1HTR1AHTR7 | |
| SCHEMBL7142406 | 0.88 | LTA4H (0.85) | LTA4H | |
| SCHEMBL4689783 | 0.85 | ESR1 (0.58) | LTA4HSIGMAR1RAB9AHRH2HRH1 | |
| SCHEMBL6943925 | 0.85 | TMEM97 (0.68) | LTA4HTMEM97SIGMAR1HTR1AHTR7 | |
| SCHEMBL8109834 | 0.85 | TMEM97 (0.68) | LTA4HTMEM97SIGMAR1HTR1AHTR7 | |
| SCHEMBL22804663 | 0.84 | LTA4H (0.63) | LTA4HSIGMAR1HTR1AHTR7KDM1A | |
| SCHEMBL12153404 | 0.84 | LTA4H (0.63) | LTA4HSIGMAR1RAB9AHRH2HRH1 | |
| SCHEMBL14570558 | 0.84 | HRH3 (0.66) | LTA4HSIGMAR1KCNA5KDM1ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9072734-B2 | Quaternary ammonium salt compounds | TEIJIN PHARMA LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| CN-102459231-B | Quaternary ammonium salt compound | TEIJIN PHARMA LTD | 2015-04-22 | — | — | CN | disclosed |
| CN-102459231-A | Quaternary ammonium salt compound | TEIJIN PHARMA LTD | 2012-05-16 | — | — | CN | disclosed |
| EP-2426121-A1 | QUATERNARY AMMONIUM SALT COMPOUND | Teijin Pharma Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | TEIJIN PHARMA LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | ADRB2, AGTR2, ADRB3 | LTA4H 2615/4885TMEM97 56/4885SIGMAR1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.